secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2022-12-29T23:59:59+00:00
Accession:  0001104659-22-130934
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel gets FDA approval for NexoBrid to treat severe thermal burns in adults
------------------------------------------------------------------------------

- FDA approved NexoBrid (anacaulase-bcdb) for eschar removal in adults with deep partial- and full-thickness thermal burns.
- Approval based on Phase 3 DETECT study meeting primary endpoint of complete eschar removal vs placebo.
- NexoBrid showed shorter time to eschar removal and lower incidence of surgical removal vs standard of care.
- Commercial launch expected in Q2 2023; company plans to establish it as new standard of care.
- Expands Vericel's target addressable market beyond sports medicine into severe burn care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000110465922130934/0001104659-22-130934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000110465922130934/tm2233709d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-130934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer